Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 31, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
LLNL, UC Davis Partner to Personalize Cancer Medications
With a $7.8 million, five-year grant from the NIH researchers are utilizing accelerator mass spectrometry for cancer research.
To Wilt or Not to Wilt
UC Riverside researchers identify new process that explains why tomatoes are susceptible to a disease-causing fungus.
A Double-edged Sword
An enzyme key to DNA repair can worsen tissue damage caused by stroke and organ transplantation.
Silencing the FOXP2 Speech Gene Causes Breast Cancer Cells to Metastasize
BIDMC investigators make the surprising discovery that a gene associated with speech and language is linked to advanced breast cancer.
Fast Modeling Of Cancer Mutations
New genome-editing technique enables rapid analysis of genes mutated in tumors.
New Test can Help Doctors Choose Best Treatment for Ovarian Cancer
ADNEX discriminate between benign and malignant tumours with a high level of accuracy.
All the Cell’s a Stage
Brian Strahl, PhD, and his band of biochemists unravel the complicated mysteries of the epigenetic code to find a culprit in cancer development.
New Cancer Drug To Begin Trials In Multiple Myeloma Patients
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.
ISB Gets $6.5 Million from NCI
Company has received two-year contract to create ‘Cancer Genomics Cloud’ with partners Google and SRA International.
Precise Control Over Genes Results from Game-Changing Research
UCSF invention greatly amplifies power of CRISPR technology.
Scroll Up
Scroll Down
Return
Therapeutic Targeting of Neuroendocrine Tumours Utilising microRNAs
Stan Sidhu, University of Sydney, speaking at Genomics Research Europe 2012
Date Posted: Friday, February 01, 2013
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Company will undertake a target discovery project for an undisclosed disease indication.
Tuesday, May 06, 2014
Cenix BioScience Joins EU FP7 Consortium for Discovery of miRNA Medicines
Company has joined an EU-funded consortium focused on the discovery of microRNA medicines in the area of cardiac and inflammatory metabolic diseases.
Wednesday, August 14, 2013
Cenix BioScience Expands Operations to U.S.
Company establishes new subsidiary named Cenix BioScience USA in Minnesota.
Friday, March 02, 2012
Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH, announced it has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Thursday, November 17, 2011
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
Collaboration and Technology License Agreement to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARE™.
Thursday, May 05, 2011
Cenix BioScience Joins EU FP7 Consortium
Consortium focused on improving the in vivo use of siRNA technology in the area of respiratory and inflammatory diseases.
Wednesday, March 30, 2011
Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
The new company accelerates the development of the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi.
Saturday, January 15, 2011
Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.
Friday, June 26, 2009
Cenix BioScience Signs Multi-Project Research Agreement with AstraZeneca
The agreement expands relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.
Tuesday, June 16, 2009
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
The research agreement comprises functional screens in human cell lines using InteRNA’s proprietary library of miRNAs.
Tuesday, November 18, 2008
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv